Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
41
ALPMY Quote, Financials, Valuation and Earnings
Last price:
$9.79
Seasonality move
:
2.7%
Day range:
$9.48 - $10.00
52-week range:
$9.15 - $13.14
Dividend yield:
4.81%
P/E ratio:
167.87x
P/S ratio:
1.55x
P/B ratio:
1.64x
Volume:
375.3K
Avg. volume:
285.2K
1-year change:
-14.27%
Market cap:
$17.5B
Revenue:
$11.1B
EPS (TTM):
$0.06
Analysts' Opinion
-
Consensus RatingAstellas Pharma has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Astellas Pharma has an estimated downside of -- from its current price of $9.79.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $9.79.
Fair Value
-
According to the consensus of 0 analysts, Astellas Pharma has -- downside to fair value with a price target of -- per share.
ALPMY vs. S&P 500
-
Over the past 5 trading days, Astellas Pharma has underperformed the S&P 500 by -0.91% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Astellas Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Astellas Pharma has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Astellas Pharma reported revenues of $3B.
Earnings Growth
-
Astellas Pharma has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Astellas Pharma reported earnings per share of $0.13.
Enterprise value:
21.7B
EV / Invested capital:
--
Price / LTM sales:
1.55x
EV / EBIT:
89.68x
EV / Revenue:
1.90x
PEG ratio (5yr expected):
--
EV / Free cash flow:
34.82x
Price / Operating cash flow:
27.42x
Enterprise value / EBITDA:
14.67x
Gross Profit (TTM):
$9.3B
Return On Assets:
0.47%
Net Income Margin (TTM):
0.92%
Return On Equity:
0.97%
Return On Invested Capital:
0.66%
Operating Margin:
10.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | $11.5B | $11B | $11.4B | $2.7B | $3B | |
| Gross Profit | $9.1B | $9.1B | $9.3B | $2.2B | $2.5B | |
| Operating Income | $1.1B | $1B | $103M | $328.3M | $306.7M | |
| EBITDA | $2.2B | $1.8B | $1.5B | $530.6M | $675.2M | |
| Diluted EPS | $0.56 | $0.42 | $0.06 | $0.13 | $0.13 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.8B | $7.8B | $7.3B | $7.5B | $8.4B | |
| Total Assets | $21.2B | $20.2B | $17.9B | $23.7B | $24.2B | |
| Current Liabilities | $5.8B | $5B | $5.3B | $7.8B | $7.7B | |
| Total Liabilities | $8.6B | $7.5B | $6.5B | $12.7B | $13.5B | |
| Total Equity | $12.6B | $12.7B | $11.4B | $11B | $10.7B | |
| Total Debt | -- | -- | -- | $6B | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.3B | $2.4B | $1.2B | $922.3M | $514.6M | |
| Cash From Investing | -$556M | -$625.8M | -$5.9B | -$187.6M | -$283.1M | |
| Cash From Financing | -$1.9B | -$1.4B | $4.3B | -$802.4M | $306M | |
| Free Cash Flow | $1.6B | $1.8B | $623.5M | $695.2M | $366.7M | |
ALPMY
Sector
Market Cap
$17.5B
$43.9M
Price % of 52-Week High
74.51%
45.73%
Dividend Yield
4.81%
0%
Shareholder Yield
6.16%
-0.74%
1-Year Price Total Return
-14.27%
-29.11%
Beta (5-Year)
0.318
0.772
Dividend yield:
4.81%
Annualized payout:
$0.46
Payout ratio:
395.08%
Growth streak:
9 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$9.93
200-day SMA
Sell
Level
$10.75
Bollinger Bands (100)
Sell
Level
10.59 - 12.19
Chaikin Money Flow
Buy
Level
7M
20-day SMA
Sell
Level
$10.22
Relative Strength Index (RSI14)
Sell
Level
32.33
ADX Line
Buy
Level
9.03
Williams %R
Neutral
Level
-76.5432
50-day SMA
Sell
Level
$10.84
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-3.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6809)
Buy
CA Score
(Annual)
Level (-0.1097)
Buy
Beneish M-Score
(Annual)
Level (-2.7167)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (2.3329)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Stock Forecast FAQ
In the current month, ALPMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ALPMY average analyst price target in the past 3 months is --.
-
Where Will Astellas Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Astellas Pharma share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Astellas Pharma?
Analysts are divided on their view about Astellas Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Astellas Pharma is a Sell and believe this share price will rise from its current level to --.
-
What Is Astellas Pharma's Price Target?
The price target for Astellas Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ALPMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Astellas Pharma is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALPMY?
You can purchase shares of Astellas Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Astellas Pharma shares.
-
What Is The Astellas Pharma Share Price Today?
Astellas Pharma was last trading at $9.79 per share. This represents the most recent stock quote for Astellas Pharma. Yesterday, Astellas Pharma closed at $9.79 per share.
-
How To Buy Astellas Pharma Stock Online?
In order to purchase Astellas Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 1.47% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 10% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 1.24% over the past day.
